Drug Profile


Alternative Names: Desvenlafaxine hydrochloride; Desvenlafaxine SR; Desvenlafaxine succinate; Desvenlafaxine succinate sustained release; Desvenlafaxine sustained-release; Desvenlaflaxine extended release; DVS-233; DVS-233 SR; DVS-SR; O-desmethylvenlafaxine; Pristiq; WY-45233

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Wyeth
  • Developer Jiangsu Hansoh Pharmaceutical; Pfizer; Wyeth
  • Class Antidepressants; Cyclohexanols; Small molecules
  • Mechanism of Action Adrenergic uptake inhibitors; Serotonin plasma membrane transport protein inhibitors; Serotonin uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Major depressive disorder; Vasomotor symptoms
  • Discontinued Fibromyalgia; Neuropathic pain

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 30 Apr 2016 Pfizer completes a phase III trial for Major depressive disorder (In children, In adolescents) in USA and Chile (NCT01371708)
  • 01 Oct 2015 Pfizer completes an extension phase III trial in Major depressive disorder (In children, In adolescents) in USA and Mexico (PO) (NCT01371721)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top